AstraZeneca gets EC marketing approval for lung cancer drug Tagrisso

AstraZeneca has received full marketing authorisation from the European Commission for Tagrisso for the treatment of adult patients with non-small cell lung cancer.

The full approval is based on the results of the Phase III AURA3 trial, which were presented last year.

The EC has given authorisation for Tagrisso 40mg and 80mg once-daily tablets.

Sean Bohen, executive vice president of Global Medicines Development and chief medical officer at AstraZeneca, said: "The full approval of Tagrisso in the EU is further evidence of our exciting progress in transforming the science of cancer care to deliver life-changing medicines to people most in need.

"Having demonstrated its superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer, Tagrisso has the potential to become the new standard of care for patients with this difficult-to-treat form of lung cancer."

At 1420 BST, the shares were up 0.9% to 4,706p.